CA2972189A1 - Combination of raf inhibitors and taxanes - Google Patents

Combination of raf inhibitors and taxanes Download PDF

Info

Publication number
CA2972189A1
CA2972189A1 CA2972189A CA2972189A CA2972189A1 CA 2972189 A1 CA2972189 A1 CA 2972189A1 CA 2972189 A CA2972189 A CA 2972189A CA 2972189 A CA2972189 A CA 2972189A CA 2972189 A1 CA2972189 A1 CA 2972189A1
Authority
CA
Canada
Prior art keywords
cancer
raf
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2972189A
Other languages
English (en)
French (fr)
Inventor
Viviana BOZON
Katherine M. Galvin
Rachael L. BRAKE
Qunli Xu
Karuppiah Kannan
Original Assignee
Millennium Pharmaceuticals Inc
Dot Therapeutics 1 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc, Dot Therapeutics 1 Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CA2972189A1 publication Critical patent/CA2972189A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2972189A 2014-12-23 2015-12-22 Combination of raf inhibitors and taxanes Abandoned CA2972189A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462096020P 2014-12-23 2014-12-23
US62/096,020 2014-12-23
US201562242629P 2015-10-16 2015-10-16
US62/242,629 2015-10-16
PCT/US2015/067462 WO2016106359A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and taxanes

Publications (1)

Publication Number Publication Date
CA2972189A1 true CA2972189A1 (en) 2016-06-30

Family

ID=56151531

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2972189A Abandoned CA2972189A1 (en) 2014-12-23 2015-12-22 Combination of raf inhibitors and taxanes

Country Status (7)

Country Link
US (2) US20190117652A1 (https=)
EP (1) EP3236966B1 (https=)
JP (2) JP2018502087A (https=)
CN (1) CN107405348B (https=)
CA (1) CA2972189A1 (https=)
ES (1) ES2827024T3 (https=)
WO (1) WO2016106359A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021108616A1 (en) * 2019-11-27 2021-06-03 Dot Therapeutics-1, Inc. Solid dispersion of pan-raf kinase inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR067354A1 (es) * 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
UA99731C2 (ru) * 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
JO3101B1 (ar) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
CN102317293A (zh) * 2008-12-05 2012-01-11 艾科尔公司 Raf抑制剂及其用途
IN2012DN01403A (https=) * 2009-08-24 2015-06-05 Genentech Inc
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
JP6835472B2 (ja) * 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
UY36046A (es) * 2014-03-26 2015-10-30 Millennium Pharm Inc Formulaciones farmacéuticas, procesos para la preparación y métodos de uso

Also Published As

Publication number Publication date
EP3236966A1 (en) 2017-11-01
JP2018502087A (ja) 2018-01-25
ES2827024T3 (es) 2021-05-19
CN107405348B (zh) 2021-06-11
EP3236966A4 (en) 2018-10-03
US20200316067A1 (en) 2020-10-08
JP2020114857A (ja) 2020-07-30
WO2016106359A1 (en) 2016-06-30
CN107405348A (zh) 2017-11-28
US20190117652A1 (en) 2019-04-25
EP3236966B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
CN106211755B (zh) 使用erk和raf抑制剂的组合的癌症治疗
EP3984537B1 (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
CN111032082B (zh) Her2阳性癌症的治疗
CN110325191A (zh) 以较少的副作用治疗egfr-驱动的癌症
JP6769962B2 (ja) 癌治療のためのキナーゼ阻害剤プロドラッグ
JP2013543008A (ja) Ｂｒａｆ阻害剤による治療方法
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
TW200908982A (en) Treatment of imatinib resistant leukemia
WO2019028055A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AC T-LYMPHOBLASTIC LYMPHOBLASTIC LEUKEMIA
WO2023114984A1 (en) Tead inhibitors and uses thereof
AU2019359872A1 (en) Compositions and methods for treating vascular Ehlers Danlos Syndrome and associated disorders
WO2021058974A1 (en) Novel treatment
US20200316067A1 (en) Combination of raf inhibitors and taxanes
BR112021011493A2 (pt) Terapia de combinação para tratamento de câncer
CN115175677A (zh) 布鲁顿氏酪氨酸激酶抑制剂的给药
WO2017066664A1 (en) Combination therapy including a raf inhibitor for the treatment of colorectal cancer
Ohno Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
EP4069243B1 (en) Combinations of etc-159 and olaparib for use in the treatment of pancreatic cancer, ovarian cancer and cholangio-carcinomas
US20250275978A1 (en) Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
WO2016106351A1 (en) Combination of raf inhibitors and mtor inhibitors
TW202602455A (zh) 使用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療
HK40068070B (en) Cancer treatments using combinations of type 2 mek and erk inhibitors
CN116940365A (zh) 慢性髓性白血病干细胞抑制剂
HK1231779B (zh) 使用erk和raf抑制剂的组合的癌症治疗

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201221

FZDE Discontinued

Effective date: 20230616